These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 3072280)

  • 1. Secondary (toxic) parkinsonism as model of Parkinson's disease.
    Riederer P; Sofic E; Heuschneider G; Benedetti MS; Dostert P
    Funct Neurol; 1988; 3(4):449-57. PubMed ID: 3072280
    [No Abstract]   [Full Text] [Related]  

  • 2. MPTP in animal models of Parkinson's disease.
    Kopin IJ; Schoenberg DG
    Mt Sinai J Med; 1988 Jan; 55(1):43-9. PubMed ID: 3126391
    [No Abstract]   [Full Text] [Related]  

  • 3. [MPTP and Parkinson's disease].
    Imai H
    No To Shinkei; 1988 Nov; 40(11):1011-24. PubMed ID: 3064783
    [No Abstract]   [Full Text] [Related]  

  • 4. MPTP-induced parkinsonism. Recent studies on the mechanism of toxicity.
    Bocchetta A; Piccardi MP; Zuddas A; Bernardi F; Zompo MD; Corsini GU
    Funct Neurol; 1988; 3(4):439-47. PubMed ID: 3072279
    [No Abstract]   [Full Text] [Related]  

  • 5. Endogenous analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: indoleamine derived tetrahydro-beta-carbolines as potential causative factors in Parkinson's disease.
    Collins MA; Neafsey EJ; Cheng BY; Hurley-Gius K; Ung-Chhun NA; Pronger DA; Christensen MA; Hurley-Gius D
    Adv Neurol; 1987; 45():179-82. PubMed ID: 3493625
    [No Abstract]   [Full Text] [Related]  

  • 6. Study on MPTP-induced parkinsonian animal model in rhesus monkey and the mechanism of MPTP.
    Chen SD; Xu DL; Yu HZ; Tang QM; Xu XR; Wang ZG; Liang PF
    Chin Med J (Engl); 1988 Dec; 101(12):879-83. PubMed ID: 3150735
    [No Abstract]   [Full Text] [Related]  

  • 7. Changes in the local cerebral metabolic rate for glucose in the MPTP primate model of Parkinson's disease.
    Schwartzman RJ; Alexander GM
    Adv Neurol; 1987; 45():171-3. PubMed ID: 3493624
    [No Abstract]   [Full Text] [Related]  

  • 8. [Experimental model of Parkinson disease induced by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
    Renkawek K
    Neuropatol Pol; 1986; 24(1):1-8. PubMed ID: 3489205
    [No Abstract]   [Full Text] [Related]  

  • 9. Autoradiographic distributions of neurotransmitter receptors in the human brains of Parkinson's disease and primate models of MPTP-induced parkinsonism.
    Kito S; Miyoshi R; Mizuno K; Nitta K; Matsubayashi H; Yamamura Y; Tahara E
    Adv Neurol; 1987; 45():159-65. PubMed ID: 2881441
    [No Abstract]   [Full Text] [Related]  

  • 10. [Parkinsonism and MPTP (methylphenyltetrahydropyridine)].
    Nagatsu T
    No To Shinkei; 1986 Jul; 38(7):706-7. PubMed ID: 3489476
    [No Abstract]   [Full Text] [Related]  

  • 11. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
    Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
    C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Parkinsonism and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (review of the literature)].
    Atadzhanov MA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1991; 91(4):117-21. PubMed ID: 1650080
    [No Abstract]   [Full Text] [Related]  

  • 13. The MPTP story: an introduction.
    Marsden CD; Sandler M
    J Neural Transm Suppl; 1986; 20():1-3. PubMed ID: 3091759
    [No Abstract]   [Full Text] [Related]  

  • 14. Parkinson-like syndrome in nonhuman primates receiving a tetrahydropyridine derivative.
    Barsoum NJ; Gough AW; Sturgess JM; de la Iglesia FA
    Neurotoxicology; 1986; 7(1):119-26. PubMed ID: 3487056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxins and Parkinson's disease: MPTP parkinsonism in humans and animals.
    Kopin IJ
    Adv Neurol; 1987; 45():137-44. PubMed ID: 3493621
    [No Abstract]   [Full Text] [Related]  

  • 16. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
    Nishi K; Kondo T; Narabayashi H
    No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MPTP: a pharmacological tool to study parkinsonism.
    Kulkarni SK; Mehta AK; Aley KO; Shukla VK
    Methods Find Exp Clin Pharmacol; 1986 Aug; 8(8):485-9. PubMed ID: 3489146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MPTP model of Parkinson's disease.
    Smeyne RJ; Jackson-Lewis V
    Brain Res Mol Brain Res; 2005 Mar; 134(1):57-66. PubMed ID: 15790530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MPTP toxicity: implications for research in Parkinson's disease.
    Kopin IJ; Markey SP
    Annu Rev Neurosci; 1988; 11():81-96. PubMed ID: 3129982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.